Health Catalyst reports preliminary 2023 revenue and EBITDA above guidance; guides 2024 EBITDA ~$25M

Health Catalyst, Inc.

Preliminary Q4 2023 total revenue above guidance midpoint (range $70.1M–$75.1M); Adjusted EBITDA at or above midpoint ($0.3M–$2.3M).
Preliminary FY 2023 total revenue above guidance midpoint ($291M–$296M); Adjusted EBITDA at or above midpoint ($10M–$12M).
2023 Dollar-Based Retention Rate approx 100%, below forecast 102%-110%, due to timing delays on large TEMS expansions.
Anticipates 2024 Adjusted EBITDA of ~$25M and 2025 Adjusted EBITDA margin target of 10% or greater.
Expects improvement in 2024 net new DOS Subscription Client bookings and retention rate relative to 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.